{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:33:25Z","timestamp":1794861205094,"version":"4.9.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02110","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T04:17:31Z","timestamp":1567743451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":73,"title":["The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity"],"prefix":"10.3389","volume":"10","author":[{"given":"Jennifer A.","family":"Jenks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie R.","family":"Permar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/cid\/civ369","article-title":"Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy","volume":"61","author":"Gnann","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1056\/NEJM198112103052403","article-title":"Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions","volume":"305","author":"Siegal","year":"1981","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","article-title":"Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for hematopoietic cell transplantation transplantation-related complication working group","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B5","volume-title":"Vaccines for the 21st Century: A Tool for Decisionmaking","author":"Stratton","year":"2000"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00705-006-0923-8","article-title":"Neutralization of animal virus infectivity by antibody","volume":"152","author":"Reading","year":"2007","journal-title":"Arch Virol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1128\/JVI.71.8.6083-6093.1997","article-title":"Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry","volume":"71","author":"Whitbeck","year":"1997","journal-title":"J Virol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.coviro.2012.01.001","article-title":"Human cytomegalovirus entry into cells","volume":"2","author":"Vanarsdall","year":"2012","journal-title":"Curr Opin Virol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-319-07911-0_8","article-title":"Glycosylation and Fc receptors","volume":"382","author":"Hayes","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nri2762","article-title":"FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/jlb.55.6.816","article-title":"Role of Fc gamma receptors in cancer and infectious disease","volume":"55","author":"Wallace","year":"1994","journal-title":"J Leukoc Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/00001813-200504000-00004","article-title":"Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction","volume":"16","author":"Tudor","year":"2005","journal-title":"Anticancer Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4049\/jimmunol.179.1.337","article-title":"Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity","volume":"179","author":"Horner","year":"2007","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2042-4280-3-5","article-title":"Herpes simplex virus and varicella zoster virus, the house guests who never leave","volume":"3","author":"Kinchington","year":"2012","journal-title":"Herpesviridae"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1128\/JVI.03163-13","article-title":"Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/infdis\/jit658","article-title":"A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes","volume":"209","author":"Awasthi","year":"2014","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of immune protection against HSV-1 genital disease in vaccinated women","volume":"209","author":"Belshe","year":"2014","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/JVI.72.1.65-72.1998","article-title":"The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge","volume":"72","author":"Peng","year":"1998","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1128\/JVI.72.5.3595-3601.1998","article-title":"Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM","volume":"72","author":"Nicola","year":"1998","journal-title":"J Virol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/infdis\/155.1.28","article-title":"Humoral and cell-mediated immunity in neonates with herpes simplex virus infection","volume":"155","author":"Sullender","year":"1987","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1099\/0022-1317-82-6-1419","article-title":"Plasma membrane requirements for cell fusion induced by herpes simplex virus type 1 glycoproteins gB, gD, gH and gL","volume":"82","author":"Browne","year":"2001","journal-title":"J Gen Virol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/v4050800","article-title":"Herpes virus fusion and entry: a story with many characters","volume":"4","author":"Eisenberg","year":"2012","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.7326\/0003-4819-122-12-199506150-00001","article-title":"A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity","volume":"122","author":"Langenberg","year":"1995","journal-title":"Ann Intern Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/infdis\/jiu177","article-title":"Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine","volume":"210","author":"Awasthi","year":"2014","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1128\/IAI.37.3.1132-1137.1982","article-title":"Protection against lethal challenge of BALB\/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2","volume":"37","author":"Balachandran","year":"1982","journal-title":"Infect Immun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/infdis\/151.3.464","article-title":"IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: role for neutralization and Fc-dependent functions but not C' cytolysis and C5 chemotaxis","volume":"151","author":"McKendall","year":"1985","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/infdis\/160.5.770","article-title":"Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection","volume":"160","author":"Kohl","year":"1989","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI114695","article-title":"Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B","volume":"86","author":"Kohl","year":"1990","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/infdis\/163.2.263","article-title":"Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies","volume":"163","author":"Mester","year":"1991","journal-title":"J Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1086\/315208","article-title":"Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine","volume":"181","author":"Kohl","year":"2000","journal-title":"J Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jri.2007.08.004","article-title":"Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms","volume":"78","author":"Chu","year":"2008","journal-title":"J Reprod Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1128\/JVI.02509-10","article-title":"The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo","volume":"85","author":"Lubinski","year":"2011","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1128\/CVI.05071-11","article-title":"Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models","volume":"18","author":"Gregg","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1128\/JVI.00186-12","article-title":"Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease","volume":"86","author":"G\u00f6rander","year":"2012","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e06054","DOI":"10.7554\/eLife.06054","article-title":"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease","volume":"4","author":"Petro","year":"2015","journal-title":"Elife"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e88529","DOI":"10.1172\/jci.insight.88529","article-title":"HSV-2 DeltagD elicits FcgammaR-effector antibodies that protect against clinical isolates","volume":"1","author":"Petro","year":"2016","journal-title":"JCI Insight"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e00411","DOI":"10.1128\/JVI.00411-17","article-title":"Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1","volume":"91","author":"Wang","year":"2017","journal-title":"J Virol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jix628","article-title":"A herpes simplex virus (HSV)-2 single-cycle candidate vaccine deleted in glycoprotein D protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2","volume":"217","author":"Burn","year":"2018","journal-title":"J Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1006601","DOI":"10.1371\/journal.ppat.1006601","article-title":"Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus","volume":"13","author":"Bootz","year":"2017","journal-title":"PLoS Pathog"},{"key":"B44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2005.05.010","article-title":"FcgammaRIV: a novel FcR with distinct IgG subclass specificity","volume":"23","author":"Nimmerjahn","year":"2005","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1462-5822.2004.00389.x","article-title":"Herpes simplex virus: receptors and ligands for cell entry","volume":"6","author":"Spear","year":"2004","journal-title":"Cell Microbiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.4049\/jimmunol.1103434","article-title":"Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity","volume":"188","author":"Moraru","year":"2012","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.4049\/jimmunol.1500872","article-title":"NK cell and Ig interplay in defense against herpes simplex virus type 1: epistatic interaction of CD16A and IgG1 allotypes of variable affinities modulates antibody-dependent cellular cytotoxicity and susceptibility to clinical reactivation","volume":"195","author":"Moraru","year":"2015","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"E4997","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine","volume":"110","author":"Freed","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1004524","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLoS Pathog"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1128\/JVI.01669-12","article-title":"A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol","volume":"87","author":"Wussow","year":"2013"},{"key":"B53","doi-asserted-by":"publisher","first-page":"17965","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000357102","article-title":"Prevention of transfusion-transmitted cytomegalovirus infections: which is the optimal strategy?","volume":"41","author":"Ziemann","year":"2014","journal-title":"Transfus Med Hemother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jmv.1890280405","article-title":"Enhanced endothelial cytopathogenicity induced by a cytomegalovirus strain propagated in endothelial cells","volume":"28","author":"Waldman","year":"1989","journal-title":"J Med Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"10489","DOI":"10.1128\/JVI.01546-13","article-title":"Impact of sequence variation in the UL128 locus on production of human cytomegalovirus in fibroblast and epithelial cells","volume":"87","author":"Murrell","year":"2013","journal-title":"J Virol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1073\/pnas.1704809114","article-title":"The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus","volume":"114","author":"Murrell","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJMoa043337","article-title":"Passive immunization during pregnancy for congenital cytomegalovirus infection","volume":"353","author":"Nigro","year":"2005","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1515\/jpm-2011-0257","article-title":"Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis","volume":"40","author":"Buxmann","year":"2012","journal-title":"J Perinat Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/infdis\/jir718","article-title":"Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy\u2013a case-control study of the outcome in children","volume":"205","author":"Nigro","year":"2012","journal-title":"J Infect Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cid\/cis423","article-title":"Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age","volume":"55","author":"Visentin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jri.2012.05.002","article-title":"A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection","volume":"95","year":"2012","journal-title":"J Reprod Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1005817","DOI":"10.1371\/journal.ppat.1005817","article-title":"Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses","volume":"12","author":"Tay","year":"2016","journal-title":"PLoS Pathog"},{"key":"B68","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1034\/j.1399-3062.2001.00006.x","article-title":"Antibody inhibition of cytomegalovirus the role of natural killer and macrophage effector cells","volume":"3","author":"Forthal","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.intimp.2004.05.020","article-title":"Herpesviral Fcgamma receptors: culprits attenuating antiviral IgG?","volume":"4","author":"Budt","year":"2004","journal-title":"Int Immunopharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00281-014-0448-2","article-title":"CMV-encoded Fcgamma receptors: modulators at the interface of innate and adaptive immunity","volume":"36","author":"Corrales-Aguilar","year":"2014","journal-title":"Semin Immunopathol"},{"key":"B72","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1128\/JVI.32.3.779-789.1979","article-title":"Membrane proteins specified by herpes simplex viruses. V. Identification of an Fc-binding glycoprotein","volume":"32","author":"Baucke","year":"1979","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/0042-6822(64)90270-3","article-title":"Inhibition of spreading of hela cells after infection with herpes simplex virus","volume":"23","author":"Watkins","year":"1964","journal-title":"Virology"},{"key":"B74","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1128\/JVI.64.6.2725-2731.1990","article-title":"Herpes simplex virus type 1 encodes two Fc receptors which have different binding characteristics for monomeric immunoglobulin G (IgG) and IgG complexes","volume":"64","author":"Dubin","year":"1990","journal-title":"J Virol"},{"key":"B75","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1128\/JVI.65.12.7046-7050.1991","article-title":"Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity","volume":"65","author":"Dubin","year":"1991","journal-title":"J Virol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e1003961","DOI":"10.1371\/journal.ppat.1003961","article-title":"The herpes virus Fc receptor gE-gI mediates antibody bipolar bridging to clear viral antigens from the cell surface","volume":"10","author":"Ndjamen","year":"2014","journal-title":"PLoS Pathog"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1371\/journal.pbio.0040148","article-title":"Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging","volume":"4","author":"Sprague","year":"2006","journal-title":"PLoS Biol"},{"key":"B78","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/JVI.63.11.4479-4488.1989","article-title":"A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G","volume":"63","author":"Frank","year":"1989","journal-title":"J Virol"},{"key":"B79","first-page":"109","article-title":"Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells","volume":"77","author":"Van Vliet","year":"1992","journal-title":"Immunology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e1006141","DOI":"10.1371\/journal.ppat.1006141","article-title":"An HSV-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in guinea pigs","volume":"13","author":"Awasthi","year":"2017","journal-title":"PLoS Pathog"},{"key":"B81","doi-asserted-by":"publisher","first-page":"10472","DOI":"10.1128\/JVI.00849-11","article-title":"Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone","volume":"85","author":"Awasthi","year":"2011","journal-title":"J Virol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1128\/JVI.01130-14","article-title":"Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"8596","DOI":"10.1128\/JVI.76.17.8596-8608.2002","article-title":"Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs","volume":"76","author":"Atalay","year":"2002","journal-title":"J Virol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"11218","DOI":"10.1128\/JVI.75.22.11218-11221.2001","article-title":"Human cytomegalovirus open reading frame TRL11\/IRL11 encodes an immunoglobulin G Fc-binding protein","volume":"75","author":"Lilley","year":"2001","journal-title":"J Virol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e50166","DOI":"10.1371\/journal.pone.0050166","article-title":"Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc","volume":"7","author":"Cortese","year":"2012","journal-title":"PLoS ONE"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1128\/JVI.01476-07","article-title":"The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G","volume":"82","author":"Sprague","year":"2008","journal-title":"J Virol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e1004131","DOI":"10.1371\/journal.ppat.1004131","article-title":"Human cytomegalovirus Fcgamma binding proteins gp34 and gp68 antagonize Fcgamma receptors I, II and III","volume":"10","author":"Corrales-Aguilar","year":"2014","journal-title":"PLoS Pathog"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02110\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T17:35:45Z","timestamp":1610991345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02110\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2019.02110"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02110","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"article-number":"2110"}}